# Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

> **NCT02861898** · PHASE1,PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 33 (estimated)

## Conditions studied

- Glioblastoma
- Brain Cancer
- Brain Neoplasm
- Brain Tumor
- Brain Neoplasm, Malignant
- EGFR Gene Overexpression
- GBM

## Interventions

- **DRUG:** Intra-arterial Cetuximab
- **DRUG:** Intra-arterial Mannitol

## Key facts

- **NCT ID:** NCT02861898
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02861898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02861898, "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02861898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*